in combination with Keytruda, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with resectable Stage II, IIIA or IIIB non-small cell lung cancer who did not achieve a pathological ...

NEW YORK – Moderna and Merck will test their personalized neoantigen cancer vaccine V940 with Merck's checkpoint inhibitor Keytruda (pembrolizumab) in certain non-small cell lung cancer patients in a ...

The two sides had played a thrilling tournament opener which Papua New Guinea won 8-2 in their first ever international Beach Soccer match. But coach Jerry Sam was without his captain Tevita ...

If you want to know where and how you can watch many of the new and recent movies streaming, then you’ve come to the right place. With so many great releases on the 2024 movie schedule, it was ...

With these approvals, KEYTRUDA is now authorized for 30 indications in the EU, including five in gynecologic cancers, Merck said in a statement. RAHWAY: Merck, also known as MSD outside the US and ...

Merck's diversified pipeline includes promising oncology candidates and a new pneumococcal vaccine, but lacks a ready-made Keytruda replacement. Investors should monitor R&D updates closely ...

On the BSE, the shares were listed at Rs 834 per share, a 73.75 percent premium over the issue price of Rs 480 per share.

Merck, known as MSD outside of the United States and Canada, announced that the European Commission (EC) has approved two new indications for Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in ...

Highlights,Merck gains two new EU approvals for KEYTRUDA in gynecologic cancers.,Approvals cover treatments for advanced endometrial and cervical cancers.,Clinical trials show significant benefits in ...

RAHWAY, N.J. - Merck, known as MSD outside the United States and Canada, has received approval from the European Commission (EC) for two new indications of its anti-PD-1 therapy, KEYTRUDA® ...